AGIO (Agios Pharmaceuticals) Short-Term Debt to Capital

Corporate company logo of Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals brings together dedicated researchers striving to combat hereditary pathologies. The specific nature of the therapy makes the business resilient to economic fluctuations, as the need for treatment remains constant. Serving as the primary valuation tool, this price chart on GURU.Markets recorded the indicator 0.02. The company is currently updating its blood medication portfolio, leveraging stable revenue from existing sales.

Ratio of Short-Term Indebtedness to Capital: Agios Pharmaceuticals Inc (AGIO) for 07/04/2022 - 10/31/2026

Analytical breakdowns for Agios Pharmaceuticals

- stock quotes and analyst forecast:
Stock Price Agios Pharmaceuticals Inc|AGIO - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Agios|AGIO - Enterprise Value
- book capitalization information:
Net Assets per Single Share Agios Pharmaceuticals|AGIO - Accounting Value of Company|Market Value to Book Value Ratio agios.com|AGIO - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Agios Pharmaceuticals|AGIO - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Agios Pharmaceuticals, Inc.|AGIO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Agios|AGIO - Company Long-Term Liabilities|Company Short-Term Debts Agios Pharmaceuticals|Quick Liquidity Indicator agios.com
- company profitability and valuation multiples indicators:
AGIO - Profit After Payment of Taxes
Fundamental valuation:AGIO Agios Pharmaceuticals Inc
Brand item of Agios

This ratio reflects the share of short-term liabilities within the equity structure, allowing for an assessment of current creditor pressure and liquidity risk. By analyzing the short-term leverage indicator, an investor can see how Agios Pharmaceuticals (AGIO) finances costly R&D processes to eventually convert drug development expenditures into high-margin global sales through patent protection.

Competitors of Agios Pharmaceuticals

Short-Term Debt to Capital ASND|MDGL (Madrigal Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CORT (Corcept Therapeutics)|Short-Term Debt to Capital rhythmtx.com RYTM|AKRO - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MTSR (Metsera, Inc.)|MoonLake Pharma (MLTX) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Crinetics Corp|NAMS (NewAmsterdam Pharma) - Short-Term Debt to Capital|Short-Term Debt to Capital soleno.life|Short-Term Debt to Equity Ratio FOLD (Amicus Therapeutics, Inc.)|ETNB (89bio Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Structure Pharma GPCR|MDXG - Short-Term Debt to Equity Ratio|Rezolute, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital lexpharma.com|MBX (MBX Biosciences) - Short-Term Debt to Equity Ratio|ALT: Short-Term Loans to Capital Ratio|AARD (Aardvark Therapeutics Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Sagimet Biosciences Inc|Short-Term Debt to Capital BIOA|Short-Term Debt to Equity BMEA (biomeafusion.com)|Short-Term Debt to Equity Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. (GUTS) - Current Liabilities to Capital|VTVT - Short-Term Debt to Equity|ATPC: Short-Term Debt to Equity|PLUR: Short-Term Debt to Capital|SYBX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipocine|Matinas BioPharma Holdings Inc. (MTNB) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Spruce Biosciences (SPRB)|Short-Term Debt to Equity Ratio Galecto Corporation GLTO|Short-Term Debt to Capital CTCX (Carmell Corporation)|Short-Term Debt to Capital lumos-pharma.com LUMO|Organovo - Short-Term Debt to Capital|Short-Term Indebtedness to Equity Radius Recycling Inc. (RDUS)